New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo

Bristol's Opdivo and Novartis/GlaxoSmithKline's Tafinlar/Mekinist combo both performed well in early, post-surgical treatment of advanced melanoma in trials reported at ESMO, promising yet another revolution in the standard of care, but leaving Roche's Zelboraf/Cotellic in the dust.

LabmicroscopeDNAgel_1200x675

Thebattle for primacy in melanoma treatment is likely to move to the early, adjuvant (post-surgical) setting, following the release of strong data for Bristol-Myers Squibb Co.'s immunotherapy Opdivo and Novartis AG/GlaxoSmithKline PLC'sBRAF and MEK inhibitors Tafinlar and Mekinist, based on full Phase III results presented at the European Society of Medical Oncology (ESMO) annual meeting.

Bristol's PD-1 inhibitor Opdivo and Novartis/Glaxo's Tafinlar (dabrafenib)/Mekinist (trametinib) combination both dramatically and significantly increased relapse-free survival (RFS) rates and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D